摘要
Tamoxifen (TAM) selectively modulates estrogen receptors and is widely used in breast cancer treatment. However, resistance to this drug appears in 40 % of estrogen receptor-positive breast cancer patients due to deregulated non-coding RNAs. This study sought to identify a long non-coding-RNA/miRNA/mRNA axis that is involved in the development of resistance to TAM- in MCF7 cells (MCF7-R).Study genes were selected using RNA-seq. The expression of genes was assessed using TCGA cohort analyses and RT-qPCR. To identify potential resistant pathways in MCF7-R, the DAVID and DIANA-miRPath were carried out. The prediction software (RNAhybrid, TargetScan, and LncTar), and RT-qPCR were used to determine the relationship between genes. Next, the MCF7-R was established and RT-qPCR, cell cycle, apoptosis, and wound healing assays were carried out to verify MCF7-R and identify the effects of CCAT2 overexpression and knockdown on the cells.Based on bioinformatics analyses, CCAT2, AKT3, and mTOR were up-regulated in breast cancer cell lines, tissues, and TAM-resistant cells, while hsa-miR-145-5p was down-regulated. According to DAVID and DIANA-miRPath, PI3K/AKT/mTOR was a pathway involved in MCF7-R. According to the prediction software, and RT-qPCR results, CCAT2/hsa-miR-145-5p and hsa-miR-145-5p/AKT3 had a negative correlation. CCAT2 knockdown could prevent cell growth, and migration, and promote apoptosis in MCF7-R, while CCAT2 overexpression induced the opposite effects. RT-qPCR revealed that the expression of BAX and Bcl-2 genes were regulated in favor of apoptosis, upon CCAT2 knockdown.CCAT2 regulates cell cycle, migration, and apoptosis in MCF7-R via the hsa-miR-145-5p/AKT3/mTOR axis. Therefore, CCAT2 may be a target to enhance the sensitivity of resistant MCF7 cells to TAM.